- Home
- GSRT vs CAPR Comparison
GSRT vs CAPR Comparison
Compare GSRT & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSRT
- CAPR
- Stock Information
- Founded
- GSRT 2023
- CAPR 2005
- Country
- GSRT United States
- CAPR United States
- Employees
- GSRT N/A
- CAPR N/A
- Industry
- GSRT
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GSRT
- CAPR Health Care
- Exchange
- GSRT Nasdaq
- CAPR Nasdaq
- Market Cap
- GSRT 302.2M
- CAPR 324.6M
- IPO Year
- GSRT 2024
- CAPR N/A
- Fundamental
- Price
- GSRT $10.37
- CAPR $6.28
- Analyst Decision
- GSRT Strong Buy
- CAPR Strong Buy
- Analyst Count
- GSRT 1
- CAPR 8
- Target Price
- GSRT $19.00
- CAPR $24.75
- AVG Volume (30 Days)
- GSRT 517.2K
- CAPR 1.4M
- Earning Date
- GSRT 01-01-0001
- CAPR 08-11-2025
- Dividend Yield
- GSRT N/A
- CAPR N/A
- EPS Growth
- GSRT N/A
- CAPR N/A
- EPS
- GSRT 0.19
- CAPR N/A
- Revenue
- GSRT N/A
- CAPR $13,392,150.00
- Revenue This Year
- GSRT N/A
- CAPR N/A
- Revenue Next Year
- GSRT N/A
- CAPR $6,061.53
- P/E Ratio
- GSRT $53.40
- CAPR N/A
- Revenue Growth
- GSRT N/A
- CAPR N/A
- 52 Week Low
- GSRT $9.86
- CAPR $3.98
- 52 Week High
- GSRT $11.49
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- GSRT 40.74
- CAPR 36.33
- Support Level
- GSRT $10.36
- CAPR $6.17
- Resistance Level
- GSRT $10.40
- CAPR $7.30
- Average True Range (ATR)
- GSRT 0.08
- CAPR 0.43
- MACD
- GSRT 0.01
- CAPR -0.11
- Stochastic Oscillator
- GSRT 14.67
- CAPR 4.53
About GSRT GSR III Acquisition Corp. Ordinary Shares
GSR III Acquisition Corp is a blank check company.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.